Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12

被引：6
|
作者：
Gnant, M.
Mlineritsch, B.
Schippinger, W.
Luschin-Ebengreuth, G.
Poestlberger, S.
Menzel, C.
Jakesz, R.
Kubista, E.
Marth, C.
Greil, R.
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Paracelsus Med Univ Salzburg, Salzburg, Austria
[3] Med Univ Graz, Graz, Austria
[4] Hosp Sisters Mercy, Linz, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.lba4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4
引用
收藏
页数：1
相关论文
共 45 条
  • [1] Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.
    Gnant, M.
    Mlineritsch, B.
    Stoeger, H.
    Luschin-Ebengreuth, G.
    Poestlberger, S.
    Dubsky, P. C.
    Jakesz, R.
    Singer, C. F.
    Eidtmann, H.
    Greil, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY
    Delea, T. E.
    Taneja, C.
    Kaura, S.
    Chatzikou, M.
    Maiadiakis, N.
    Fagoulakis, V
    VALUE IN HEALTH, 2009, 12 (07) : A270 - A270
  • [3] The number needed to treat (NNT) as a measure of drug efficacy: the case of zoledronic acid for early hormone-responsive breast cancer in the ABCSG-12 trial
    Gnant, M.
    Mlineritsch, B.
    Schippinger, W.
    Luschin-Ebengreuth, G.
    Steger, G.
    Bjelic-Radisic, V
    Jakesz, R.
    Kubista, E.
    Marth, C.
    Greil, R.
    CANCER RESEARCH, 2009, 69 (02) : 191S - 191S
  • [4] Number needed to treat (NNT) as a drug efficacy measure: Zoledronic acid (ZOL) for early hormone-responsive breast cancer in the ABCSG-12 trial
    Gnant, M.
    Mlineritsch, B.
    Schippinger, W.
    Luschin-Ebengreuth, G.
    Steger, G.
    Bjelic-Radisic, V.
    Jakesz, R.
    Kubista, E.
    Marth, C.
    Greil, R.
    BREAST, 2009, 18 : S59 - S59
  • [5] ADJUVANT ENDOCRINE THERAPY, ALONE OR IN COMBINATION WITH ZOLEDRONIC ACID (ZOL), IN PREMENOPAUSAL PATIENTS (PTS) WITH ENDOCRINE-RESPONSIVE EARLY BREAST CANCER (EBC): SUBGROUP ANALYSES OF ABCSG-12
    Gnant, M.
    Mlineritsch, B.
    Stoeger, H.
    Luschin-Ebengreuth, G.
    Poestlberger, S.
    Steger, G. G.
    Jakesz, R.
    Singer, C. F.
    Eidtmann, H.
    Greil, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 79 - 79
  • [6] Cost-effectiveness of adding zoledronic acid to endocrine therapy in premenopausal women with hormone-responsive early breast cancer in Portugal, Spain, and Italy, based on the ABCSG-12 Study
    Delea, T. E.
    Tanaja, C.
    Kaura, S.
    Sternini, P.
    Gerzeli, S.
    Gnant, M.
    EJC SUPPLEMENTS, 2010, 8 (03): : 63 - 64
  • [7] Cost-Effectiveness of Adding Zoledronic Acid to Endocrine Therapy in Premenopausal Women with Hormone-Responsive Early Breast Cancer in Sweden, Norway, Denmark, and Finland, Based on the ABCSG-12 Study
    Taneja, C.
    Lindman, H.
    Paija, O.
    Kamby, C.
    Kaura, S.
    Jnosson, L.
    Delea, T.
    CANCER RESEARCH, 2009, 69 (24) : 735S - 736S
  • [8] 62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer
    Gnant, M.
    Mlineritsch, B.
    Stoeger, H.
    Luschin-Ebengreuth, G.
    Poestlberger, S.
    Steger, G.
    Jakesz, R.
    Singer, C.
    Eidtmann, H.
    Greil, R.
    BONE, 2011, 48 (01) : S17 - S17
  • [9] Zoledronic acid combined with adjuvant tamoxifen with or without ovarian function suppression in premenopausal early breast cancer patients
    El-Ibrashi, M. M.
    El-Sadda, W. M.
    Abdel-Halim, I. I.
    Elashri, M. S.
    CANCER RESEARCH, 2016, 76
  • [10] Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: Quality of life and efficacy tradeoffs
    Elkin, EB
    Weinstein, MC
    Kuntz, KM
    Bunnell, CA
    Weeks, JC
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) : 25 - 34
12345